BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 23, 2009
View Archived Issues
BioCryst $49M Public Offering Cashes in on Stock Momentum
BioCryst Pharmaceuticals Inc. priced a $49 million public offering, cashing in on the 593 percent gain its shares have posted so far this year thanks to progress with flu drug peramivir. (BioWorld Today)
Read More
Lawmakers Suspect 'Back-door' Move to Recoup Drug Price Cuts
Read More
Novavax $21M Stock Sale Would Fund U.S. Filing for VLP Vaccine
Read More
In Today's 'Bench Press': Tech Transfer Impact
Read More
Corrections & Clarifications
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Appointments And Advancements
Read More
Bench Press
Read More